Holen Sie sich die Stockscreener-App
4.65
1.69%
-0.07
Schlusskurs vom Vortag:
$4.72
Offen:
$4.77
24-Stunden-Volumen:
605.04K
Relative Volume:
0.84
Marktkapitalisierung:
$178.36M
Einnahmen:
$114.20M
Nettoeinkommen (Verlust:
$-3.08M
KGV:
-11.97
EPS:
-0.3885
Netto-Cashflow:
$-77.20M
1W Leistung:
+10.48%
1M Leistung:
+49.68%
6M Leistung:
+16.58%
1J Leistung:
+174.56%
1-Tages-Spanne:
$4.56
$5.08
1-Wochen-Bereich:
$3.855
$5.08
52-Wochen-Spanne:
$1.60
$7.34
Agenus Inc Stock (AGEN) Company Profile
Firmenname
Agenus Inc
Sektor
Branche
Telefon
781-674-4410
Adresse
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
4.645 | 181.24M | 114.20M | -3.08M | -77.20M | -0.3885 |
VRTX
Vertex Pharmaceuticals Inc
|
437.99 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
744.72 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
845.38 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
332.36 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.26 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-02-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-28 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-04-22 | Eingeleitet | B. Riley FBR | Buy |
| 2016-10-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Bestätigt | Maxim Group | Buy |
| 2016-03-11 | Hochstufung | Maxim Group | Hold → Buy |
| 2015-12-16 | Eingeleitet | Jefferies | Buy |
| 2015-10-27 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-07-27 | Bestätigt | MLV & Co | Buy |
| 2015-06-11 | Eingeleitet | Oppenheimer | Outperform |
| 2015-01-12 | Bestätigt | Maxim Group | Buy |
| 2015-01-09 | Bestätigt | MLV & Co | Buy |
| 2015-01-09 | Bestätigt | Maxim Group | Buy |
| 2014-12-19 | Bestätigt | Maxim Group | Buy |
| 2014-05-08 | Bestätigt | Maxim Group | Buy |
| 2014-03-14 | Bestätigt | MLV & Co | Buy |
| 2013-10-08 | Bestätigt | Maxim Group | Buy |
| 2012-01-05 | Eingeleitet | William Blair | Outperform |
| 2011-12-01 | Eingeleitet | Global Hunter Securities | Buy |
Alle ansehen
Agenus Inc Aktie (AGEN) Neueste Nachrichten
Agenus (AGEN) presents new phase 1b clinical data on BOT/BAL combination for MSS mCRC - MSN
Director Harrison of AGENUS INC (AGEN) granted 9,228 shares as board fees - Stock Titan
Agenus (AGEN) price target increased by 25.68% to 15.81 - MSN
Technical Analysis: Should you avoid Agenus Inc stock right nowQuarterly Investment Review & Growth-Oriented Investment Plans - baoquankhu1.vn
Armen of Agenus (NASDAQ: AGEN) takes salary in stock - Stock Titan
New Phase II Data on BOT/BAL Combination in Gastroesophageal Cancer at AACR 2026Agenus - Oncodaily
Agenus receives $20M payment under Zydus Life Sciences collaboration - MSN
Buybacks Report: How sensitive is Agenus Inc to inflation2026 Sector Moves & AI Based Trade Execution Alerts - baoquankhu1.vn
Setup Watch: Can Agenus Inc deliver consistent EPS growth2026 Biggest Moves & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Weekly Earnings: Should you avoid Agenus Inc stock right nowPortfolio Performance Report & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Everything Important About Agenus (AGEN) Receiving a Strong Buy Rating Upgrade - Bitget
Agenus unveils Phase II data for BOT BAL and MiNK iNKT therapy in PD-1 refractory cancer - Traders Union
Can Agenus (AGEN) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Agenus Announces Data from Phase II Study of BOT+BAL in Combinati - The National Law Review
All You Need to Know About Agenus (AGEN) Rating Upgrade to Strong Buy - Yahoo Finance
Why Agenus (AGEN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Phase 3 BATTMAN Trial Launches BOT/BAL in MSS or pMMR Metastatic Colorectal Cancer - Oncodaily
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 - The AI Journal
HC Wainwright Analysts Boost Earnings Estimates for Agenus - MarketBeat
Has Agenus (AGEN) Surpassed Other Healthcare Stocks So Far This Year? - Bitget
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer - 뉴스와이어
Agenus Inc. (AGEN) stock price, news, quote and history - Yahoo Finance UK
Agenus (NASDAQ: AGEN) director awarded 2,448 Deferred Stock Units as board pay - Stock Titan
Agenus Inc. Initiates Landmark Phase 3 BATTMAN Trial In MSS Metastatic Colorectal Cancer - BioPharma APAC
Portfolio Update: Is Agenus Inc benefiting from interest rate changes2026 Final Week & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Agenus begins phase 3 trial for colorectal cancer treatment By Investing.com - Investing.com South Africa
Agenus Enrolls First Patient in Phase 3 BATTMAN Trial for MSS/pMMR Metastatic Colorectal Cancer - Oncodaily
Agenus (AGEN) Launches Global Phase 3 Trial for Innovative Cance - GuruFocus
Agenus (AGEN) Launches Global Phase 3 Trial for Innovative Cancer Treatment - GuruFocus
Agenus Inc Announces First Patient Enrolled In Global Phase 3 BATTMAN Trial Of BOT Plus BAL Immunotherapy Combination In MSS Or PMMR Metastatic Colorectal Cancer - marketscreener.com
Can Agenus' BOT + BAL Immunotherapy Turn Cold Tumors Hot? - RTTNews
Agenus Launches Landmark Global Phase 3 Clinical Trial - Intellectia AI
Agenus begins phase 3 trial for colorectal cancer treatment - Investing.com
Agenus AGM: Bot/Bal Combo Targets “Cold” MSS Colorectal Cancer as Phase III BATMAN Trial Launches - MarketBeat
Agenus announced that the first patient has been enrolled in its global Phase III Battman trial. - Bitget
Agenus (NASDAQ:AGEN) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Finanzdaten der Agenus Inc-Aktie (AGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.60%
1.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):